Daiichi Sankyo sees ENHERTU sales reaching ¥539.9B in FY2024 amid oncology momentum
Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...
Trump tariffs on chips and drugs would hit US allies in Asia
US President Donald Trump announced plans to impose tariffs on imported computer chips pharmaceuticals and steel aiming to drive more manufacturing within the United States ...
Malaysia Sun10h
US allies in Asia would suffer with Trump tariffs on chips, drugs
U.S. President Donald Trump announced plans to impose tariffs on imported computer chips, pharmaceuticals, and steel, aiming to drive more manufacturing within the United States ...
manilatimes21h
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...
FiercePharma23h
Merck vaccine, Daiichi ADC win approval recommendations in busy week at EU's drug regulator
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Hosted on MSN20h
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...
ENDPOINTS NEWS22h
Dai­ichi Sankyo taps new CEO, aims to build up ADC fran­chise
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently Daiichi’s chief operating officer.
Reuters23h
Asia Pacific
Myanmar's ruling military has extended a state of emergency for another six months, state media reported on Friday, a day ahead of the four-year anniversary of a coup that plunged the country into ...